Ranbaxy Lipitor Settlement With Pfizer Could Double Indian Firm Sales
This article was originally published in PharmAsia News
Executive Summary
The patent suit settlement Pfizer against Ranbaxy Laboratories could mean sales by India's largest drug maker will double within the next three years. The settlement ended Pfizer's suit against Ranbaxy and its generic of the U.S. company's Lipitor (atorvastatin). Last year, Lipitor brought $12.7 billion in sales to Pfizer, so the settlement allowing Ranbaxy to market a generic ahead of the expiration date for the drug patent could earn the Indian drug maker $2 billion, more than the firm's $1.78 billion in sales last year. Ranbaxy is allowed to begin marketing its generic in Canada after Nov. 30, and in the U.S. after Nov. 30, 2011. (Click here for more